Takeda Pharmaceutical (TAK) Gains from Investment Securities (2018 - 2026)

Takeda Pharmaceutical's Gains from Investment Securities history runs 9 years deep, the most recent figure standing at $4.1 million for Q1 2026.

• On a quarterly basis, Gains from Investment Securities rose 1914.71% year-over-year to $4.1 million in Q1 2026; TTM through Mar 2026 was $8.6 million, a 106.44% increase from a year earlier, with the FY2026 full-year figure at $8.6 million, up 106.85% from the prior year.
• Gains from Investment Securities climbed to $4.1 million in Q1 2026 per TAK's latest filing, from $467848.8 in the prior quarter.
• Across five years, Gains from Investment Securities topped out at $85.4 million in Q1 2024 and bottomed at $6704.1 in Q3 2024.
• The 5-year median for Gains from Investment Securities is $2.4 million (2025), against an average of $8.4 million.
• Across the five-year window, Gains from Investment Securities surged 60397.32% in 2022 and sank 99.76% in 2025, its largest moves.
• Year by year, Gains from Investment Securities stood at $5.8 million in 2022, then slumped by 55.19% to $2.6 million in 2023, then grew by 0.52% to $2.6 million in 2024, then plunged by 82.08% to $467848.8 in 2025, then jumped by 775.01% to $4.1 million in 2026.
• Per Business Quant, the three latest TAK Gains from Investment Securities figures stand at $4.1 million (Q1 2026), $467848.8 (Q4 2025), and $2.3 million (Q3 2025).